Developing innovative drugs for the treatment of Crohn's Disease, COVID-19, Progressive Multiple Sclerosis (pro-MS) and Hepatocellular Carcinoma (HCC)

Learn more about Tiziana

TR-1: Standard form for notification of major holdings

10 August 2020

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

...

Read more

Closing of $57.25 Million Offering

05 August 2020

London, New York 5 August 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces the closing of its registered...

Read more

Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients

04 August 2020

Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients

  • Recently signed agreements with four contract research organizations (“CROs”) to...
Read more

Our Mission

Our mission is to bring breakthrough therapies to patients with the aim of treating Crohn's Disease, COVID-19, Pro-MS and HCC and optimizing health outcomes.

Learn more

Clinical Candidates

With two Phase II and two pre-clinical candidates our development portfolio is supported by extensive IP and a strong pipeline of in-licensed clinical and pre-clinical assets.

Clinical development pipeline

Foralumab

Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of Crohn’ s Disease and a neurodegenerative indication.

Learn more about Foralumab

Milciclib

Milciclib is the Company’s Phase 2 clinical candidate for the treatment of multiple cancer indications such as hepatocellular carcinoma, thymic cancer and thymoma.

Learn more about Milciclib

Pre-Clinical Candidates

With several candidates being prepared for clinic, our development portfolio is supported by extensive IP and a strong pipeline of in-licenced clinical and pre-clinical assets.

Anti IL-6R mAb (TZLS-501)

We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6 as a potential treatment for certain patients infected with COVID-19.

Learn more about Anti IL-6R

StemPrintER™

StemPrintER is a multi-gene signature assay intended for use as a prognostic in patients with estrogen-receptor positive ER+/HER2 negative breast cancers.

Learn more about StemPrintER™

Clinical Trials

Tiziana is currently conducting clinical development programs for Foralumab and Milciclib

Foralumab

Tiziana reported postive clinical data in a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston. Phase 2 for both orally administered Foralumab for the treatment of Crohn's disease and nasally administered Foralumab for the treatment of Pro-MS is anticipated to be complete in Q2 2021.

See more Foralumab clinical trials

Milciclib

We reported positive Phase 2a clinical data exhibiting positive clinical activity with Milciclib Monotherapy in advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma. We intend to initiate Phase 2b with Milciclib in Combination with a TKI in Q2 2021

See more Milciclib clinical trials

Tiziana Life Sciences is listed on NASDAQ and AIM